Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Spyre Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 84 | 78 | −6 |
| Shares | 41.5M | 41.1M | −436.4K (−1.1%) |
| Value | $328.7M | $285.8M | −$42.9M (−13.0%) |
New holders (3)
Institutions that held Spyre Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ergoteles LLC | 34,100 | $237.0K | 0.01% |
| Cerity Partners LLC | 18,000 | $125.0K | 0.00% |
| Invesco Ltd. | 13,045 | $90.0K | 0.00% |
Sold out (9)
Institutions that held Spyre Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Driehaus Capital Management LLC | 175,000 | $1.39M |
| State of Wisconsin Investment Board | 60,300 | $478.0K |
| Two Sigma Advisers, LP | 33,800 | $268.0K |
| MetLife Investment Management | 20,285 | $160.7K |
| Two Sigma Investments, LP | 18,332 | $145.0K |
| Metropolitan Life Insurance Co | 12,039 | $95.3K |
| Engineers Gate Manager LP | 10,800 | $86.0K |
| Bank of Montreal | 3,727 | $29.0K |
| FNY Investment Advisers, LLC | 1,500 | $11.0K |